ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "clinical trials and monoclonal antibodies"

  • Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting

    PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease

    Ian Bruce1, Alireza Nami 2, Erik Schwetje 3, M Edward Pierson 4, Yen Lin Chia 5, Denison Kuruvilla 5, Gabriel Abreu 6, Raj Tummala 3 and Catharina Lindholm 6, 1University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 2Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, 3AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, 4AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, 5AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, 6AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences